Adverse Drug Reaction Classification System

ADR Ontology
ADR Term Head and neck cancer
ADR ID BADD_A06467
ADR Hierarchy
16      Neoplasms benign, malignant and unspecified (incl cysts and polyps)
16.16      Miscellaneous and site unspecified neoplasms malignant and unspecified
16.16.01      Neoplasms malignant site unspecified NEC
16.16.01.003      Head and neck cancer
Description Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651) [MeSH]
MedDRA Code 10067821
MeSH ID D006258
ADR Severity Grade (FAERS)
ADR Severity Grade (CTCAE) Not Available
Synonym
Malignant neoplasm of head, face, and neck | Malignant neoplasm of head, face, and neck NOS | Head and neck cancer | Head and Neck Neoplasms | Neoplasms, Head and Neck | Head, Neck Neoplasms | Cancer of Head and Neck | Head and Neck Cancer | Cancer of the Head and Neck | Upper Aerodigestive Tract Neoplasms | UADT Neoplasms | Neoplasm, UADT | Neoplasms, UADT | UADT Neoplasm | Neoplasms, Upper Aerodigestive Tract | Head Neoplasms | Neoplasms, Head | Neck Neoplasms | Neoplasms, Neck | Cancer of Head | Head Cancer | Cancer of the Head | Cancer of Neck | Neck Cancer | Cancer of the Neck
ADR Related Proteins
Protein Name UniProt AC TTD Target ID
Not AvailableNot AvailableNot Available
Drugs Leading to the ADR
Drug IDDrug NameADR Frequency (FAERS)ADR Severity Grade (FAERS)
BADD_D00014Abiraterone0.000384%
BADD_D00156Apremilast0.000453%
BADD_D00349Capecitabine0.000139%
BADD_D00511Clozapine0.002924%
BADD_D00567Dabrafenib mesylate--
BADD_D00775Enzalutamide0.000576%
BADD_D00800Erlotinib0.000139%
BADD_D00879Fentanyl0.000252%
BADD_D01253Lenalidomide--
BADD_D01322Losartan0.000025%
BADD_D01567Nilotinib0.000278%
BADD_D01601Olaparib0.000139%
BADD_D01905Raltegravir0.001971%
BADD_D02029Sitagliptin0.000065%
BADD_D02100Sunitinib0.000139%
BADD_D02252Tositumomab--
The 1th Page    1    Total 1 Pages